Batten Disease Treatment Market size is expected to grow at a CAGR of 5.4% during the forecast period 2022 to 2028. The global market provides a detailed overview and which can be segmented by type of disease, treatment, distribution channel, and region. By type of disease, the market has been segmented into juvenile NCL (JNCL), infantile NCL (INCL), late infant NCL (LINCL), adult NCL, and others. By treatment, the adult NCL segment held the largest revenue share of the batten disease treatment market in historic years and is expected to have a significant growth rate over the forecasted period due to the rising adult population suffering from batten disease. By treatment, the has been segmented into gene therapy, drug therapy, enzyme therapy, and others. By treatment, the drug therapy segment held the maximum revenue share of the batten disease treatment market and is anticipated to have a significant growth rate during the forecasted period due to continuous advancement in drug therapy by increasing investment in the healthcare system. By distribution channel, the batten disease treatment market has been segmented into hospital pharmacies, retail pharmacies, and others. By treatment type, the hospital segment held the largest revenue share of the batten disease treatment market in past years and is expected to have the fastest growth rate over the forecasted period due to a high patient population proportion worldwide.
In June 2021 – Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its adeno-associated virus (AAV) encoding a codon-optimized human CLN5 transgene (hCLN5) for patients diagnosed with CLN5, a subtype of Batten disease.